SBSara Becker

Sara Becker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sara Becker has a total of 74 co-authors. Here are the top co-authors by number of shared publications:

  • Inga Liepelt-Scarfone

    Hertie Institute for Clinical Brain Research, Tuebingen, Germany 2

    5 shared publications
  • Inga Liepelt-Scarfone

    Tübingen, Germany)

    4 shared publications
  • Kathrin Brockmann

    German Center of Neurodegenerative Diseases (DZNE), Hertie Institute for Clinical Brain Research, Department of Neurodegenerative Diseases, University of Tübingen, Hoppe-Seyler-Str. 3, 72076, Tübingen, Germany

    4 shared publications
  • Anja Ophey

    Medical Psychology | Neuropsychology and Gender Studies, Center for Neuropsychological Diagnostics and Intervention (CeNDI), Faculty of Medicine and University Hospital Cologne, University of Cologne Cologne Germany

    3 shared publications
  • Daniela Berg

    Department of Neurology, Christian-Albrechts-University, Kiel, Germany

    3 shared publications
  • Walter Maetzler

    Department of Neurology, University Hospital Schleswig-Holstein, Christian-Albrechts-University, Arnold-Heller-Str. 3, 24105, Kiel, Germany

    3 shared publications

Latest Publications

  • Open Access

    Understanding the pattern of cognitive decline in GBA1-related Parkinson’s Disease: a longitudinal multi-cohort study

    by Merle Bode, Claire Pauly, Sonja Rós Jónsdóttir, Claudia Schulte, Sara Becker, Isabel Wurster, Benjamin Roeben, Stefanie Lerche, Werner Poewe, Rejko Krüger, et al.

    Objective: People with Parkinson’s disease (PD) who carry a pathogenic GBA1 variant (PD GBA1 ) are at higher risk of cognitive impairment than those without the variant (PD GBA1_wildtype ). To date, little is known about the pattern and evolution of cognitive decline in PD GBA1 . This multi-center study characterized the cognitive profile of PD GBA , focusing on the longitudinal trajectories and the group-specific onset times among cognitive functions, as well as their clinical relevance. Methods: In this longitudinal multicohort-study (PPMI, ABC-PD, Luxembourg Parkinson’s Study), comprehensive neuropsychological assessments were standardized across 548 healthy controls (follow-up-years=2.84±4.33), 906 PD GBA1_wildtype (follow-up-years=4.29±4.16), and 210 PD GBA1 (follow-up-years=4.09±3.35). We evaluated performance across age and disease duration using regression (generalized) linear mixed models within each cognitive domain. Time-to-first-event models, assessing risks of clinically relevant performance impairment (test-score z ≤-1.5, MoCAGBA1 showed lower performance in attention (processing speed) and memory (verbal learning) than PD GBA1_wildtype , but more widespread probability of performance impairment. Over time, attention, visuoperception, memory, and semantic fluency performance declined more rapidly in PD GBA1 compared to PD GBA1_wildtype . Impairment in processing speed occurred earlier in the disease process of PD GBA1 . Risks for clinically relevant cognitive impairment in PD GBA1 during the disease course were generally increased. Moderate-to-strong correlations between cognitive functions were observed within and across cognitive domains in PD GBA1 and PD GBA1_wildtype , particularly in attentional-executive functions. Interpretation: PD GBA1 exhibits accelerated domain-generalized cognitive decline compared to PD GBA1_wildtype , with susceptibility of semantic fluency, attention, and memory. Summary for Social Media: If you and/or a co-author has a X handle that you would like to be tagged, please enter it here. (format: @AUTHORSHANDLE) . None What is the current knowledge on the topic? (one to two sentences) Pathogenic coding variants in the Glucocerebrosidase (GBA1) gene in Parkinson’s Disease (PD-GBA1) are linked to more severe cognitive impairment. However, the domain-specific trajectories of cognitive decline are currently unknown. What question did this study address? (one to two sentences) This study aimed to analyze the course of longitudinal cognitive profile in PD-GBA1 across disease duration and age in regard to cognitive domains and clinical relevance. What does this study add to our knowledge? (one to two sentences) PD-GBA1 exhibits accelerated cognitive decline with susceptibility of semantic fluency, attention, and memory. Cognitive decline risk elevated 2-to-3 years post-diagnosis. How might this potentially impact on the practice of neurology? (one to two sentences) The results can help to identify individuals at risk of cognitive decline and to better design clinical trials aiming at disease modification with cognition as endpoint.

  • Open Access

    Mid- and late-life lifestyle activities as main drivers of general and domain-specific cognitive reserve in individuals with Parkinson’s disease: cross-sectional and longitudinal evidence from the LANDSCAPE study

    by Anja Ophey, Kathrin Wirtz, Steffen Wolfsgruber, Monika Balzer-Geldsetzer, Daniela Berg, Rüdiger Hilker-Roggendorf, Jan Kassubek, Inga Liepelt-Scarfone, Sara Becker, Britt Mollenhauer, et al.

    Background: Cognitive reserve (CR) is considered a protective factor for cognitive function and may explain interindividual differences of cognitive performance given similar levels of neurodegeneration, e.g., in Alzheimer´s disease. Recent evidence suggests that CR is also relevant in Parkinson’s disease (PD). Objective: We aimed to explore the role of life-stage specific CR for overall cognition and specific cognitive domains cross-sectionally and longitudinally in PD. Methods: The cross-sectional analysis with data from the DEMPARK/LANDSCAPE study included 81 individuals without cognitive impairment (PD-N) and 87 individuals with mild cognitive impairment (PD-MCI). Longitudinal data covered 4 years with over 500 observations. CR was operationalized with the Lifetime of Experiences Questionnaire (LEQ), capturing the complexity of lifestyle activities across distinct life-stages. Cognition was assessed using a comprehensive neuropsychological test battery. Results: Higher LEQ scores, particularly from mid- and late-life, were observed in PD-N compared to PD-MCI [F(1,153) = 4.609, p = .033, ηp2 = 0.029]. They were significantly associated with better cognitive performance (0.200 ≤ β ≤ 0.292). Longitudinally, linear mixed effect models (0.236 ≤ marginal R2 ≤ 0.441) revealed that LEQ scores were positively related to cognitive performance independent of time. However, the decline in overall cognition and memory over time was slightly more pronounced with higher LEQ scores. Conclusions: This study emphasizes the association between complex lifestyle activities and cognition in PD. Data indicate that while CR might be related to a delay of cognitive decline, individuals with high CR may experience a more pronounced drop in overall cognition and memory. Future studies will have to replicate these findings, particularly regarding domain-specific effects and considering reverse causal mechanisms.


  • Multidomain cognitive training increases physical activity in people with Parkinson's disease with mild cognitive impairment

    by Merle Bode, Patricia Sulzer, Claudia Schulte, Sara Becker, Kathrin Brockmann, Saskia Elben, Ann-Kristin Folkerts, Anja Ophey, Christian Schlenstedt, Karsten Witt, et al.


  • Open Access

    Cognitive-Driven Activities of Daily Living Impairment as a Predictor for Dementia in Parkinson Disease

    by Sara Becker, Merle Bode, Kathrin Brockmann, Thomas Gasser, Katja Michaelis, Susanne Solbrig, Hans-Christoph Nuerk, Claudia Schulte, Walter Maetzler, Milan Zimmermann, et al.

    Background and Objectives One-third of Parkinson disease (PD) patients with PD-mild cognitive impairment (PD-MCI) convert to dementia within a few years. Markers with a high prognostic value for dementia conversion are needed. Loss of everyday function primarily caused by cognitive dysfunction is the core criterion for the diagnosis of PD dementia, with an onset of more complex instrumental activities of daily living (IADL) dysfunction in the prodromal stage. This study evaluated the phenotype associated with cognitive IADL impairment and its predictive value for defining a high-risk group for PD dementia. Methods An observational longitudinal study using cognitive and clinical scores in addition to genetic and CSF biomarkers was conducted. The Functional Activities Questionnaire quotient (cut-off ≥1), indicating more cognitive than motor-driven IADL impairment, defined cognitive IADL impairment status at baseline. Hazard ratios (HRs) were used to compare the impact of baseline classifications on dementia conversion. Results Of 268 patients with PD assessed at baseline, 108 (40.3%) had PD-MCI. After a period of 3.78 ± 0.84 years, 164 (61.2%) patients were reassessed. At follow-up, 93 (56.7%) patients had no cognitive impairment, 54 (32.9%) fulfilled PD-MCI criteria, and 17 (10.4%) had developed dementia. The HR of baseline cognitive IADL impairment (n = 37) for dementia conversion was descriptively higher than for PD-MCI, but highest in patients with both markers (HR = 12.01, 95% CI 4.47–32.22, p < 0.001). In the follow-up sample, nearly half of the patients (n = 10, 47.6%) with baseline classification of cognitive IADL impairment and PD-MCI converted to dementia. Baseline status of cognitive IADL impairment was associated with higher nonmotor burden, worse cognitive performance, and more severe IADL progression over the study period. Discussion The importance of differentiating between cognitive and motor aspects on ADL function in PD and monitoring cognitive ADL impairment in the prodromal stage of dementia is paramount. Patients with PD-MCI and cognitive IADL impairment may be a valuable target group for clinical trials aiming to slow down the development of dementia. Trial Registration Information ClinicalTrials.govNCT03687203. Classification of Evidence This study provides Class II evidence that impairment of cognitive activities of daily living is associated with progression from MCI to dementia among patients with Parkinson disease.


  • Evaluation of the Dementia Apraxia Test in Parkinson’s Disease Patients

    by Daniela Renftle, Sara Becker, Kathrin Brockmann, Thomas Gasser, Katja Michaelis, Susanne Solbrig, Patricia Sulzer, Andreas Johnen, Inga Liepelt-Scarfone

    Introduction: Ideomotor apraxia, a disorder of skilled movements affecting limbs and/or face, can be seen in patients with Parkinson’s disease (PD), yet tests of apraxia in PD are rare. The aim of this project was to evaluate the psychometric properties and validity of the Dementia Apraxia Test (DATE) in a PD sample. Methods: 118 PD patients were included. Besides DATE performance, motor and non-motor burden, cognition, and activity of daily living (ADL) function were assessed. Patients were classified as cognitively impaired (n = 41) or non-cognitively impaired (n = 77). Results: Interrater reliability of the DATE (sub-)scores between video ratings and on-site ratings by the investigator was good (0.81 ≤ rk ≤ 0.87). Items were mostly easy to perform, especially the buccofacial apraxia items, which had also low discriminatory power. DATE scores were associated with cognition and ADL function. DATE performance was confounded by motor impairment and patients’ age; however, when analysed for both cognitive groups separately, the correlation between DATE and motor performance was not significant. Discussion/Conclusion: The DATE seems to be an objective and predominantly valid apraxia screening tool for PD patients, with a few items needing revision. Due to the potential effect of motor impairment and age, standardized scores adjusting for these confounders are needed.


  • A new CERAD total score with equally weighted z-scores and additional executive and non-amnestic „CERAD-Plus“ tests enhances cognitive diagnosis in patients with Parkinson's disease: Evidence from the LANDSCAPE study

    by Robert Lillig, Anja Ophey, Jörg B. Schulz, Kathrin Reetz, Jennifer Wojtala, Alexander Storch, Inga Liepelt-Scarfone, Sara Becker, Daniela Berg, Monika Balzer-Geldsetzer, et al.


  • Association of Hippocampal Subfields, CSF Biomarkers, and Cognition in Patients With Parkinson Disease Without Dementia

    by Sara Becker, Oliver Granert, Maarten Timmers, Andrea Pilotto, Luc Van Nueten, Benjamin Roeben, Giacomo Salvadore, Wendy R. Galpern, Johannes Streffer, Klaus Scheffler, et al.


  • Association of cognitive activities of daily living (ADL) function and nonmotor burden in nondemented Parkinson’s disease patients.

    by Sara Becker, Alena Bäumer, Walter Maetzler, Susanne Nussbaum, Zuzanna Tkaczynska, Patricia Sulzer, Maarten Timmers, Luc Van Nueten, Giacomo Salvadore, Kathrin Brockmann, et al.

    In Parkinson's disease (PD), nonmotor symptoms (NMS) considerably influence disease progression and cognitive decline. Depression, anxiety, sleep disturbances, and hallucinations (DASH), may indicate a risk for dementia (PDD). Mild impairments in activities of daily living (ADL) caused by cognitive dysfunction are also present in the prodromal stage of PDD. The association of both factors has been sparsely investigated. Aim was to evaluate these specific NMS in a large nondemented PD cohort and their co-occurrence with cognitive dysfunction and ADL impairments. Data of 226 PD patients was analyzed. Using corresponding items, two DASH scores were constructed from the NMS-Scale and Parkinson's disease Questionnaire (PDQ-39). Correlations between DASH scores and PDD risk factors were examined. PD patients with mild cognitive impairment (PD-MCI) were additionally split into patients with low and high DASH burden, the latter group additionally stratified by presence of cognitive-driven ADL impairment. DASH-NMS scores differed significantly between PD-MCI and cognitively normal (PD-CN) patients (p = .04), while the DASH-PDQ did not (p = .73). The only significant predictor of the DASH-NMS score was cognitive-driven ADL (p = .01). PD-MCI patients with a high DASH burden and more cognitive ADL impairment presented with worse global cognition than patients with a low burden (p = .045). Our results show that the DASH-NMS is superior to the DASH-PDQ score, related to the severity of cognitive impairment, and strongly influenced by cognitive-driven ADL impairment. Presence of DASH symptoms and cognitive-ADL in PD-MCI patients may define a risk group for PDD conversion. (PsycInfo Database Record (c) 2020 APA, all rights reserved).